Pyxis OncologyPYXS
Market Cap: $206M
About: Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
Employees: 55
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
9,133% more call options, than puts
Call options by funds: $1.66M | Put options by funds: $18K
56% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 16
13% more funds holding
Funds holding: 71 [Q1] → 80 (+9) [Q2]
8.25% more ownership
Funds ownership: 39.52% [Q1] → 47.77% (+8.25%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
5% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 21
5% less capital invested
Capital invested by funds: $97.9M [Q1] → $93.1M (-$4.78M) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Swayampakula Ramakanth 36% 1-year accuracy 49 / 135 met price target | 100%upside $7 | Buy Reiterated | 16 Aug 2024 |
Stifel Bradley Canino 52% 1-year accuracy 16 / 31 met price target | 186%upside $10 | Buy Initiated | 8 Aug 2024 |